Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.
Last trade$0.61
Day change+$0.016 (+2.69%)
Day range$0.568 – $0.622
Volume86,266
Market cap$4M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$3.83M
Price / earnings
—
Price / book
1.46×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.41×
Profitability
Earnings per share
-$2.32
Return on assets
-125.36%
Return on equity
-574.08%
Dividend yield
0%
Liquidity and leverage
Debt / equity
2.38×
Current ratio
1.38×
Quick ratio
1.38×
Cash ratio
0.95×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$13.95M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for IMNN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$1.66M
$1.33M
$1.97M
$1.77M
$1.58M
$1.54M
$1.98M
$1.91M
Research and development
$1.79M
$1.46M
$2.34M
$2.49M
$1.9M
$1.23M
$2.17M
$2.23M
Total operating expenses
$3.45M
$2.79M
$4.31M
$4.26M
$3.48M
$2.77M
$4.15M
$4.15M
Operating income
-$3.45M
-$2.79M
-$4.31M
-$4.26M
-$3.48M
-$2.77M
-$4.15M
-$4.15M
Interest expense
-$264.13K
-$77.27K
$0
$0
$0
$0
$0
$0
Income before taxes
-$3.75M
-$2.81M
-$4.25M
-$4.22M
-$3.43M
-$2.74M
-$4.1M
-$4.06M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$3.75M
-$2.81M
-$4.25M
-$4.22M
-$3.43M
-$2.74M
-$4.1M
-$4.06M
Net income attributable to common shareholders
-$3.75M
-$2.83M
-$4.25M
-$4.22M
-$3.43M
-$2.74M
-$4.1M
-$4.06M
EBITDA
-$3.38M
-$2.72M
-$4.24M
-$4.19M
-$3.4M
-$2.69M
-$4.08M
-$4.11M
Basic earnings per share
-$0.64
-$0.54
-$0.84
-$1.42
-$1.16
-$2.15
-$3.15
-$2.44
Diluted earnings per share
-$0.64
-$0.54
-$0.84
-$1.42
-$1.16
-$2.15
-$3.15
-$2.44
Recent news
Company coverage with links to the original publishers.
IMUNON reported Q3 2026 financial results with a net loss of $3.8 million. The company highlighted progress in its Phase 3 OVATION 3 trial of IMNN-001, a DNA-based immunotherapy for advanced ovarian cancer, with enrollment expected to complete by Q1 2029. Recent developments include a collaboration with the National Cancer Institute, positive Phase 2 data showing overall survival benefits, and strategic moves to strengthen financial position including transitioning ThermoDox to VoxelDox and completing a debt-for-equity exchange.
IMUNON announced new translational data from its Phase 2 OVATION 2 study showing that IMNN-001, when combined with standard chemotherapy, increased anti-tumor T-cell activity and improved median overall survival by 14.7 months in advanced ovarian cancer patients. The data demonstrates the drug's mechanism of converting the tumor microenvironment from immunologically 'cold' to 'hot,' supporting the ongoing Phase 3 OVATION 3 trial.
IMUNON, Inc. (Nasdaq: IMNN) announced a conference call scheduled for March 31, 2026 at 11:00 a.m. EDT to discuss 2025 financial results and provide updates on its Phase 3 clinical trial (OVATION 3) for IMNN-001, a DNA-based IL-12 immunotherapy for advanced ovarian cancer treatment.
IMUNON announced progress in its Phase 3 OVATION 3 clinical trial for IMNN-001, a DNA-mediated immunotherapy targeting advanced ovarian cancer. The company has enrolled its first patient, implemented cost conservation measures, and introduced a 15% stock dividend to shareholders.
IMUNON, a clinical-stage biotechnology company, announced a $3.25 million private placement and the potential for an additional $6.5 million from the exercise of short-term warrants. The company plans to use the proceeds for working capital and general corporate purposes.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.